LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has retained Hayden IR, a national, New York-based investor relations consulting firm, to develop an investor relations program to raise the company’s visibility and strengthen its relationships with the investment community.
Walt Woltosz, chairman and chief executive officer of Simulations Plus, commented: “Simulations Plus has demonstrated the consistent ability to generate earnings and cash, while strengthening its balance sheet and improving its strategic position. We continue to expand our product line and services and add to our Life Sciences team, setting the stage for accelerating top-line growth. Our Board of Directors is committed to translating this performance into enhanced shareholder value, and we believe the time is right to engage Hayden IR to broaden our exposure with investors. Hayden IR comes highly recommended as an agency that can introduce us to new institutional shareholders who will understand our strategy and embrace our business model.”
With offices in New York, Phoenix, Minneapolis and San Diego, Hayden IR provides a comprehensive range of investor relations services to a growing list of clients. For more than a decade, Hayden IR has been a recognized leader in driving market recognition and creating sustainable competitive advantages for more than 100 micro- and small-cap companies. Hayden delivers expertise and professionalism in such areas as investor management, relationship building, awareness campaigns, online presence and corporate identity.
Jeffrey Stanlis, Partner at Hayden IR, added: “Simulations Plus represents an exciting opportunity for investors to benefit from, and participate in, technology advances in the life sciences and pharmaceutical development. We believe this is a compelling investment for a wide range of small-cap and mid-cap investors. Simulations Plus has demonstrated an ability to grow revenue—while maintaining 70+% gross margin and solid double-digit operating margin—even in a challenging economy. Its best-in-class pharmaceutical software offerings continue to create opportunities for continuing growth with leading pharmaceutical organizations. In fiscal 2009, the company generated more than $1.5 million in cash even after increasing research and development spending, marketing and sales activities, and funding more than $1 million for share repurchases. The Company built on this success with record revenue and profitability in the first quarter of fiscal 2010. We believe Simulations Plus is well-positioned for the future and represents an exciting, high-margin investment in an industry segment with compelling long-term trends.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. We have two other businesses that are based on our proprietary technologies: a wholly owned subsidiary, Words+, Inc., which provides assistive technologies to persons with disabilities; and an educational software series for science students in middle and high schools known as FutureLab™. For more information, visit our Web site at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.simulations-plus.com&esheet=6189443&lan=en_US&anchor=www.simulations-plus.com&index=1&md5=a133985ea5fbcf3199df3670b5400970.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission